POEMS Syndrome

Every Cure will leverage Google Cloud's infrastructure and AI technologies, including Gemini 2.0, to accelerate discoveries and improve patient outcomes PHILADELPHIA and SUNNYVALE, Calif., Jan. 13, 2025 /PRNewswire/ -- Every Cure, a leading nonprofit dedicated to identifying and validating new uses for existing drugs, today announced an expanded collaboration with Google Cloud to advance AI-driven drug repurposing. By leveraging Google Cloud's AI tools, including Gemini 2.0 large language models to power Every Cure's MATRIX platform, Every Cure aims to accelerate the discovery, validation, and global dissemination of life-saving treatments for diseases lacking effective therapies. More than 300 million people globally suffer from diseases without available treatments, while many face barriers to accessing existing therapies. Drug repurposing utilizes existing medicines, which are often affordable, widely accessible generics with established safety profiles and extensive data, to address this unmet need. By combining Every Cure's mission-driven expertise with Google Cloud's advanced AI capabilities, the collaboration seeks to transform healthcare delivery and patient outcomes worldwide. Every Cure researchers use Google Cloud's infrastructure to stay at the cutting edge of drug repurposing, an approach that can bypass the prolonged timelines and high costs associated with traditional drug development. The Every Cure Leadership Team has already advanced over a dozen repurposed treatments for diseases they weren't initially intended for, including Castleman disease, DADA2 syndrome, POEMS syndrome, and angiosarcoma. By leveraging iterative learning cycles, Every Cure will not only advance computational biology but also deliver immediate benefits to patients with Google Cloud. "We are so excited about the potential for this collaboration with Google Cloud to rapidly scale the impact that Every Cure can make on patients' lives. We created Every Cure to treat patients with existing drugs as quickly as possible and this collaboration supercharges our ability to do this," said Every Cure Co-Founder & President David Fajgenbaum, MD, MBA, MSc. This collaboration focuses on three key use cases: Improving accuracy of AI-driven drug repurposing predictions Every Cure's MATRIX platform will use Google Cloud's AI technology, including Gemini 2.0, to analyze complex biomedical knowledge and integrate diverse data sources, including omics datasets, clinical data, real-world evidence and biomedical knowledge graphs. This synergy will enhance prediction accuracy, identifying overlooked therapeutic opportunities, and accelerating hypothesis generation. Validating predictions through accelerated preclinical testing and optimized clinical trials By leveraging Gemini 2.0-driven trial design and predictive analytics, Every Cure will streamline in vitro and in vivo preclinical testing and clinical trial workflows to confirm efficacy and safety of repurposed drugs. Every Cure will also use Google Cloud's AI-powered tools to select optimal trial designs, reducing resource use and ensuring more efficient evaluation of treatments. Ensuring global adoption of validated treatments to save lives With the help of Google Cloud's scale and infrastructure, Every Cure will ensure that validated repurposed drugs are rapidly adopted into clinical practice, particularly in underserved regions. A few examples of Google Cloud and Workspace tools that are used as part of this collaboration are Google Kubernetes Engine (including GPUs), Ray on VertexAI, BigQuery and Cloud Storage to facilitate the secure dissemination of clinical guidelines. Meanwhile Data Studio provides visual dashboards for global stakeholders. "Every Cure is doing incredible work with the power of cloud and AI technologies by repurposing medicine to save lives," said Scott Penberthy, Senior Director of Applied AI, Office of the CTO, Google Cloud. "We're delighted customers are tapping into the power of GPUs, TPUs, search and AI models that have been purpose built for Google systems, now available on Google Cloud. We are proud to collaborate with them on this journey." This collaboration builds on a successful collaboration between Every Cure and Google Cloud. Google Cloud has supported Every Cure with infrastructure and services to manage biomedical datasets and execute complex computations. With the help of Gemini 2.0's advanced capabilities, Every Cure aims to transform healthcare by accelerating the pace of innovation while ensuring that breakthroughs reach patients worldwide. Every Cure has already identified a number of promising drug repurposing opportunities through its AI-powered pipeline for diseases with major unmet need that are undergoing further investigation, including a neurodevelopmental disorder involving folate receptor auto-antibodies which can be helped with a generic drug that repletes the folate deficiency and can address neurodevelopmental challenges in these patients. About Every Cure Every Cure is a nonprofit biotech organization committed to unlocking the potential of existing medicines to treat as many diseases as possible. By harnessing AI-driven platforms, rigorous preclinical and clinical testing, and global dissemination strategies, Every Cure accelerates the delivery of life-saving treatments to patients worldwide. Every Cure has been profiled on Good Morning America, USA Today, and the Wall Street Journal and selected as both an Audacious Project grantee from TED and a Founder's Prize recipient from Elevate Prize Foundation. Learn more at . Media Contact: [email protected] SOURCE Every Cure WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Molecular glue refers to a class of small molecules that connect two or more proteins in a paste-like manner. Molecular glue can enhance and stabilize protein interactions; it can also repair protein interactions that have been weakened due to mutations. Furthermore, it induces the interaction of E3 ubiquitin ligase with protein targets, triggering target protein polyubiquitination and subsequent degradation by the proteasome. Molecular glue can also regulate protein functions; for example, PKM2 is a pyruvate kinase related to cancer. Its activity is low in homodimer form, but molecular glue can stabilize the dimer and "glue" two dimers together to form PKM2 homotetramer, thus increasing enzyme activity. Targeted Protein Degradation (TPD) is a rapidly developing drug discovery strategy, using small molecules to recruit E3 ubiquitin ligase and promote protein hydrolysis. It has great potential in the treatment of tumors, infectious diseases, inflammation, and neurodegenerative diseases, and can break through the "undruggable" problem. With the rise of molecular glue degraders, these can induce or stabilize protein-protein interactions (PPI) between ubiquitin ligase and target proteins (substrates), leading to protein ubiquitination and subsequent proteasome degradation. Currently, several pharmaceutical companies are laying out in this field, mobilizing efforts to develop new therapies to meet unmet clinical needs. Protein-Protein Interactions (PPIs) are vitally important for many cellular processes. Dysregulation of these interactions often leads to the onset of various diseases, such as cancer and Alzheimer's disease among others. Hence, when the dysregulation of protein interactions provokes disease, the development of drugs to regulate these interactions becomes a clinical target that needs to be addressed. Currently, the vast majority of drugs are protein inhibitors. However, many of the proteins causing disease are challenging to target with traditional small molecule drugs, these proteins are often referred to as "undruggable" targets.  Molecular glues can be utilized to develop drugs to target some of these "undruggable" entities. Molecular glues can enhance and stabilize Protein-Protein Interactions (PPIs), repair Protein-Protein Interactions (PPIs), and promote new Protein-Protein Interactions (PPIs). Molecular glues can regulate protein function by inhibiting or activating protein companions or by recruiting E3 ubiquitin ligase to degrade targeted protein complexes. Rationally designing molecular glues remains and will continue to be a challenge.  At present, most molecular glues and their mechanisms of action are typically discovered by chance. And screening for molecular glues involves high-throughput screening of small molecule compound libraries, a process akin to searching for a needle in a haystack. Looking forward, studying protein-protein interactions and the functional tertiary structure is crucial for designing molecular glues in a high-throughput fashion. We anticipate being able to more efficiently screen and even rationally design brand new molecular glues based on substrate structure in the future, for degrading a large number of "undruggable" disease targets in the body. Molecular Glue Competitive LandscapeAccording to Patsnap Synapse, as of 8 Oct 2023, there are a total of 57 Molecular glue drugs worldwide, from 53 organizations, covering 29 targets, 78 indications, and conducting 2089 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications,  targets, organizations, clinical trials, and clinical results related to this drug type. Approved Molecular Glue Medicinal: PomalidomidePomalidomide is a small molecule drug classified as a molecular glue. It targets several proteins including CRBN, IL-6, TNF, and TNF-α. The drug has shown potential in treating various therapeutic areas such as neoplasms, immune system diseases, nervous system diseases, hemic and lymphatic diseases, infectious diseases, cardiovascular diseases, and other diseases. Pomalidomide has been indicated for the treatment of relapse multiple myeloma, Kaposi Sarcoma, multiple myeloma, medulloblastoma, Hodgkin's Lymphoma, and non-Hodgkin lymphoma. It was developed by Celgene Corp., a pharmaceutical company known for its expertise in the field of biomedicine. The drug has received approval for its highest phase in global market. Its first approval was granted in the United States in February 2013. Pomalidomide has undergone various regulatory processes, including priority review, accelerated approval, fast track, and orphan drug designation. Pomalidomide's approval for multiple indications suggests its potential in addressing various diseases. Its small molecule nature and molecular glue classification indicate its ability to interact with specific proteins, potentially leading to therapeutic benefits. The drug's targeting of CRBN, IL-6, TNF, and TNF-α suggests its involvement in modulating immune responses and inflammatory processes. Overall, Pomalidomide is a small molecule drug with a molecular glue classification that targets multiple proteins. Its approval for various therapeutic areas and indications suggests its potential in treating a wide range of diseases. The drug's regulatory designations and approval in multiple countries further support its potential as a valuable treatment option in the pharmaceutical industry. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. LenalidomideLenalidomide is a small molecule drug classified as a molecular glue. It targets several proteins including CK1α, CRBN, IFNγ, IKZF1, IKZF3, IL-2, IL-6, and TNF-α. The drug has shown potential in treating various therapeutic areas such as neoplasms, immune system diseases, nervous system diseases, congenital disorders, hemic and lymphatic diseases, and cardiovascular diseases. Lenalidomide has been approved for multiple indications globally, including Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, Adult T-Cell Leukemia-Lymphoma, Peripheral T-Cell Lymphoma, Mantle-Cell Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Indolent Non-Hodgkin Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma, B-Cell Chronic Lymphocytic Leukemia, B-Cell Lymphoma, and POEMS Syndrome. The drug was first approved in the United States in December 2005 and has since gained approval in other countries. Lenalidomide is developed by Celgene Corp., which is the originator organization responsible for its discovery and development. Lenalidomide has received regulatory designations such as Orphan Drug, Priority Review, and Special Review Project. These designations highlight the drug's potential to address unmet medical needs and expedite the regulatory review process. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. In summary, Lenalidomide is a small molecule drug developed by Celgene Corp. It targets several proteins and has been approved for various therapeutic areas, including neoplasms, immune system diseases, nervous system diseases, congenital disorders, hemic and lymphatic diseases, and cardiovascular diseases. The drug has received regulatory designations and was first approved in the United States in 2005. Its ability to act as a molecular glue and target multiple proteins makes it a promising option for the treatment of several diseases.

Tumor Necrosis Factor (TNF) is a protein produced by immune cells in the human body. It plays a crucial role in regulating inflammation and immune responses.  TNF acts as a signaling molecule, binding to specific receptors on cells and triggering a cascade of events that promote inflammation. It helps in the defense against infections and plays a role in the destruction of cancer cells.  However, excessive or prolonged TNF activity can lead to chronic inflammation and contribute to various diseases, including autoimmune disorders like rheumatoid arthritis and inflammatory bowel disease. Pharmaceutical interventions targeting TNF have been developed to modulate its activity and treat these conditions. TNF Competitive LandscapeAccording to the data provided by Patsnap Synapse-Global Drug Intelligence Database: the following figure shows that as of 3 Sep 2023, there are a total of 83 TNF drugs worldwide, from 100 organizations, covering 90 indications, and conducting 843 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. The analysis of the target TNF from various perspectives provides valuable insights into the current competitive landscape and future development. Bristol Myers Squibb Co., INmune Bio, Inc., and other companies are actively involved in the development of TNF drugs. Multiple indications have approved drugs, indicating the potential therapeutic benefits of targeting TNF. Small molecule drugs, molecular glues, and biosimilars are progressing rapidly, suggesting intense competition in the market. Japan, the United States, and the European Union are leading in terms of approved drugs, with China also making progress. This analysis sets the stage for further research and development in the field of TNF-targeted therapies. Key Drug: ThalidomideThalidomide is a small molecule drug classified as a molecular glue that primarily targets TNF (tumor necrosis factor). It has been approved for use in various therapeutic areas, including cardiovascular diseases, congenital disorders, hemic and lymphatic diseases, respiratory diseases, infectious diseases, skin and musculoskeletal diseases, neoplasms, immune system diseases, and nervous system diseases. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. The drug has shown efficacy in treating several active indications, such as POEMS syndrome, leprosy (lepromatous), multiple myeloma, erythema nodosum, ankylosing spondylitis, idiopathic pulmonary fibrosis, and telangiectasia, hereditary hemorrhagic. Thalidomide's approval for these indications has been granted by regulatory authorities in multiple countries, including the United States. Celgene Corp. is the originator organization of Thalidomide, which has successfully developed and brought the drug to market. Thalidomide has reached the highest phase of development, with global and Chinese approvals. The drug received its first approval in the United States in July 1998. Thalidomide's regulatory status includes accelerated approval and orphan drug designation. Accelerated approval allows for the expedited review and approval of drugs that address unmet medical needs, while orphan drug designation provides incentives for the development of drugs targeting rare diseases. PomalidomidePomalidomide is a small molecule drug classified as a molecular glue. It targets several proteins including CRBN, IL-6, TNF, and TNF-α. The drug has shown potential in treating various therapeutic areas such as neoplasms, immune system diseases, nervous system diseases, hemic and lymphatic diseases, infectious diseases, cardiovascular diseases, and other diseases. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Pomalidomide has been indicated for the treatment of relapse multiple myeloma, Kaposi Sarcoma, multiple myeloma, medulloblastoma, Hodgkin's Lymphoma, and non-Hodgkin lymphoma. It was developed by Celgene Corp., a pharmaceutical company known for its expertise in the field of biomedicine. The drug has received approval for its highest phase in both the global market and China. Its first approval was granted in the United States in February 2013. Pomalidomide has undergone various regulatory processes, including priority review, accelerated approval, fast track, and orphan drug designation. Overall, Pomalidomide's approval and its broad therapeutic areas of application make it a promising drug in the pharmaceutical industry. Its development by Celgene Corp., a reputable organization in the field, further adds to its credibility. Further research and clinical trials may provide more insights into its efficacy and potential applications in the future.